PT 11

Drug Profile

PT 11

Latest Information Update: 18 Feb 2008

Price : $50

At a glance

  • Originator Palatin Technologies
  • Class
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Bacterial infections

Most Recent Events

  • 05 Oct 2001 No-Development-Reported for Diagnostic imaging in Japan (Unknown route)
  • 03 Dec 1998 Preclinical development for Diagnostic imaging in Japan (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top